TSRLabs
TSRLabs is a woman-owned preclinical contract research organization (CRO) based in Ann Arbor, Michigan. The company provides integrated early-stage development services — including formulation development, high-sensitivity bioanalysis, pharmacokinetics/ADME, exploratory toxicology, strategic consulting, and drug delivery system development — to pharmaceutical, biotechnology, academic, and government partners. TSRLabs emphasizes data generation and risk reduction to inform candidate-advancement decisions in preclinical development.
Industries
Nr. of Employees
small (1-50)
Products
Proprietary microneedle / microarray patch (MAP) delivery platform
A transdermal microneedle/microarray patch platform under development for weekly or other sustained dosing applications; development includes licensing, co-development, and grant-supported projects.
sHDL (synthetic high-density lipoprotein) lead candidate (SPS-701) program
Preclinical development program for a synthetic high-density lipoprotein candidate intended to address infection complications such as sepsis; funded via a Direct-to-Phase II NIH award to advance toward GLP toxicology.
Proprietary microneedle / microarray patch (MAP) delivery platform
A transdermal microneedle/microarray patch platform under development for weekly or other sustained dosing applications; development includes licensing, co-development, and grant-supported projects.
sHDL (synthetic high-density lipoprotein) lead candidate (SPS-701) program
Preclinical development program for a synthetic high-density lipoprotein candidate intended to address infection complications such as sepsis; funded via a Direct-to-Phase II NIH award to advance toward GLP toxicology.
Services
High-sensitivity quantification of small molecules and biological samples using HPLC and LC-MS/MS to support PK, safety, and toxicology studies.
Formulation design and optimization to improve solubility, stability, and delivery characteristics for preclinical candidates.
Program planning and scientific guidance to close knowledge gaps, align nonclinical data with regulatory expectations, and support development decisions.
Development and co-development of novel delivery systems, including microneedle/microarray patch (MAP) approaches for transdermal drug administration.
Design and conduct of absorption, distribution, metabolism, excretion, and exploratory toxicology studies to inform human dosing strategies and support regulatory planning.
High-sensitivity quantification of small molecules and biological samples using HPLC and LC-MS/MS to support PK, safety, and toxicology studies.
Formulation design and optimization to improve solubility, stability, and delivery characteristics for preclinical candidates.
Program planning and scientific guidance to close knowledge gaps, align nonclinical data with regulatory expectations, and support development decisions.
Development and co-development of novel delivery systems, including microneedle/microarray patch (MAP) approaches for transdermal drug administration.
Design and conduct of absorption, distribution, metabolism, excretion, and exploratory toxicology studies to inform human dosing strategies and support regulatory planning.
Expertise Areas
- Preclinical development
- Formulation development and solubility optimization
- Drug delivery systems (transdermal microneedle/MAP)
- Bioanalysis and mass spectrometry
Key Technologies
- Liquid chromatography (HPLC)
- Tandem mass spectrometry (LC-MS/MS)
- Mass spectrometry-based analytics
- Microneedle / microarray patch (MAP) delivery technology
News & Updates
Announcement that an emerging company established operations within TSRLabs' Ann Arbor facility to enable co-location and collaboration.
Public announcement of corporate rebranding to TSRLabs, including updated identity and website to reflect expanded laboratory and development capabilities.
TSRL participated in a published study reporting in vitro activity of a methionyl-tRNA synthetase inhibitor against resistant gram-positive organisms.
Company CEO discussed TSRLabs' early-stage drug development work and microneedle patch efforts on an Ann Arbor podcast.
Award of a Phase II SBIR grant (R44) to advance a microneedle patch program for overactive bladder therapy.
Company has secured multiple NIH grants across programs, including awards to support microneedle patch development, sHDL program advancement, and antibacterial/antiviral projects.
Announcement that an emerging company established operations within TSRLabs' Ann Arbor facility to enable co-location and collaboration.
Public announcement of corporate rebranding to TSRLabs, including updated identity and website to reflect expanded laboratory and development capabilities.
TSRL participated in a published study reporting in vitro activity of a methionyl-tRNA synthetase inhibitor against resistant gram-positive organisms.
Company CEO discussed TSRLabs' early-stage drug development work and microneedle patch efforts on an Ann Arbor podcast.
Award of a Phase II SBIR grant (R44) to advance a microneedle patch program for overactive bladder therapy.
Company has secured multiple NIH grants across programs, including awards to support microneedle patch development, sHDL program advancement, and antibacterial/antiviral projects.